Pear Therapeutics

Jim Breidenstein

Jim Breidenstein has been recognized as a strategic executive leader and driving force in the success of novel medical device and med-tech companies from early stage commercial development thru acquisition or IPO. Currently Jim serves as VP, Global Commercial Development for Pear Therapeutics where he leads commercial efforts as Pear creates and leads a new class of therapeutics.

Prior to joining Pear, Jim served as the Chief Commercial Officer of CHF-Solutions (CHFS) where he led a comprehensive relaunch of the company and an innovative product offering. Jim also spent time at Surgical Theater, a novel virtual reality based advanced imaging company as the President and Chief Operating Officer. He provided executive leadership and operational oversight to this privately held healthcare company as he created the corporate and commercial strategies.

In addition, Jim was Senior Vice President of Cardiovascular Systems (CSII), a developer of a novel system of interventional technologies for treatment of cardiovascular disease. In that role, he led the company’s dramatic turnaround from $40 million to more than $200 million annual revenue, while managing a staff of more than 200 employees.

Jim also served as Vice President of Sales & Customer Operations at Neuronetics, a VC backed startup company offering the industry’s first and only medical device to the field of psychiatry for the treatment of depression. Jim joined Kyphon (KYPH) prior to FDA approval and spend 7 years in various executive leadership roles including General Manager, Vice President, and National Sales Director. Kyphon achieved annual sales of $470 million and was acquired  for $4.2 billion dollars.

Jim holds a BA in Business Studies from State University College in Buffalo, New York. He has completed the Executive Educational Program in Marketing Healthcare Products at The Kellogg School of Management at Northwestern University.

Back